This evolving treatment landscape has altered the relevance of predictive markers such as TP53 mutations and del(17p), yet disease relapse remains a significant challenge due to the substantial heterogeneity of CLL and the complex interplay of genetic resistance mechanisms and pathway-adaptive resistance mechanisms. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.